Core Viewpoint - Zhejiang Medicine (600216.SH) has received approval from the National Medical Products Administration for the clinical trial of XC2309 injection, indicating progress in its drug development pipeline [1] Company Summary - Zhejiang Medicine has successfully obtained the clinical trial approval for XC2309 injection, which meets the requirements for drug registration [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of XC2309 injection, which is intended for treating gastrointestinal ulcer bleeding [1] Summary by Categories Regulatory Approval - The National Medical Products Administration has issued a clinical trial approval notice for XC2309 injection, confirming that the application meets the requirements for drug registration [1] Product Development - XC2309 injection is designed to address gastrointestinal ulcer bleeding caused by various conditions [1] - The company has invested a total of 83.9607 million yuan in the research and development of the XC2309 project to date [1]

Core Viewpoint - Zhejiang Medicine has shown a net financing inflow of 16.134 million yuan last week, ranking 494th in the market, indicating a moderate interest from investors [1] Financing and Investment Summary - The total financing amount for Zhejiang Medicine last week was 265 million yuan, while the repayment amount was 249 million yuan [1] - Over the past 5 days, the main capital outflow was 9.0568 million yuan, with a decline of 0.52% in this period [1] - In the last 10 days, the main capital outflow reached 134 million yuan, reflecting a decline of 3.43% [1] Company Profile - Zhejiang Medicine Co., Ltd. was established in 1997 and is located in Shaoxing City, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 961.63775 million yuan, which is also its paid-in capital [1] - The legal representative of the company is Li Nanhang [1] Business Activities - Zhejiang Medicine has made investments in 28 enterprises and participated in 83 bidding projects [1] - The company holds 190 trademark registrations and 27 patents, along with 46 administrative licenses [1]

Group 1 - The core viewpoint of the news highlights the financial performance and stock activity of Zhejiang Medicine Co., Ltd. as of August 13, 2025, showing a stock price increase and significant net profit growth [1] - As of the first quarter of 2025, the company reported total revenue of 2.255 billion yuan, a year-on-year increase of 0.28%, and a net profit attributable to shareholders of 409 million yuan, reflecting a substantial year-on-year growth of 273.08% [1] - The company's liquidity ratios are strong, with a current ratio of 2.854 and a quick ratio of 1.999, indicating good short-term financial health [1] Group 2 - Zhejiang Medicine has made investments in 28 companies and participated in 83 bidding projects, showcasing its active engagement in the market [2] - The company holds 190 trademark registrations and 27 patents, indicating a focus on intellectual property and innovation [2] - Additionally, Zhejiang Medicine has obtained 46 administrative licenses, reflecting its compliance and operational capabilities [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 三、回购期间相关主体买卖股票情况 2025年4月15日，公司首次披露了回购股份方案，具体内容详见公司在上海证券交易所网站披露的《浙 江医药股份有限公司关于以集中竞价交易方式回购股份方案的公告》(公告编号：2025-008)。 ■ 一、回购审批情况和回购方案内容 浙江医药股份有限公司（以下简称"公司"）于2025年4月14日召开第十届四次董事会会议，审议通过了 《关于以集中竞价交易方式回购股份方案的议案》，同意公司使用自有资金或自筹资金以集中竞价交易 方式回购公司股份，用于后续实施员工持股计划或股权激励，回购价格不超过人民币20.83元/股 （含），回购资金总额不低于人民币1亿元（含）且不超过人民币2亿元（含），回购期限自董事会审议 通过回购股份方案之日起不超过12个月，即2025年4月15日-2026年4月14日。本次回购股份事项的具体 内容详见公司于2025年4月19日在上海证券交易所网站披露的《浙江医药股份有限 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600216 证券简称：浙江医药 公告编号：2025-033 公司实施2024年年度权益分派后，公司以集中竞价交易方式回购股份价格上限由不超过人民币20.83元/ 股（含）调整为不超过人民币20.46元/股（含）。具体内容详见公司于2025年7月15日在上海证券交易 所网站披露的《浙江医药股份有限公司关于2024年年度权益分派实施后调整回购股份价格上限的公告》 （公告编号：2025-030）。 二、回购实施情况 2025年5月12日，公司首次实施回购股份，具体内容详见公司于2025年5月13日在上海证券交易所网站披 露的《浙江医药股份有限公司关于以集中竞价交易方式首次回购公司股份的公告》(公告编号：2025- 018)。 2025年8月11日，公司完成回购，通过上海证券交易所系统以集中竞价方式累计回购公司股份13,723,200 股，占公司目前总股本的1.43%，回购最高价格为16.09元/股，最低价格为13.31元/股，回购均价为14.57 元/股，使用资金总额为人民币199,982,725元(不含交易费用)。 公司本次回购股份符合相关法律法规的规 ...

证券日报网讯8月12日晚间，浙江医药（600216）发布公告称，2025年8月11日，公司完成回购，通过上 海证券交易所系统以集中竞价方式累计回购公司股份13，723，200股，占公司目前总股本的1.43%。 ...

Group 1 - The company Zhejiang Medicine announced the completion of a share buyback on August 11, 2025, through the Shanghai Stock Exchange [1] - A total of 13.72 million shares were repurchased, accounting for 1.43% of the company's total share capital [1] - The highest buyback price was 16.09 CNY per share, the lowest was 13.31 CNY per share, and the average buyback price was 14.57 CNY per share, with a total expenditure of approximately 200 million CNY (excluding transaction fees) [1] Group 2 - The repurchased shares will be used for future employee stock ownership plans or equity incentives [1]

Core Viewpoint - Zhejiang Medicine announced the completion of a share buyback, acquiring approximately 13.72 million shares, which represents 1.43% of the company's total equity, at an average price of 14.57 CNY per share, totaling around 200 million CNY in funds used [1] Group 1: Share Buyback Details - The company completed the buyback on August 11, 2025, through a centralized bidding method on the Shanghai Stock Exchange [1] - The highest buyback price was 16.09 CNY per share, while the lowest was 13.31 CNY per share [1] - The total number of shares repurchased was approximately 13.72 million [1] Group 2: Revenue Composition - For the year 2024, the revenue composition of Zhejiang Medicine is as follows: human nutritional products accounted for 50.1%, pharmaceuticals for 48.85%, and other businesses for 1.05% [1] - The contribution from other businesses includes 0.64% from other categories and 0.41% from additional services [1] Group 3: Market Capitalization - As of the report, Zhejiang Medicine's market capitalization stands at 15 billion CNY [1]

证券代码：600216 证券简称：浙江医药 公告编号：2025-033 浙江医药股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案首次披露日 2025/4/15，由公司董事长李男行先生提议 回购方案实施期限 2025 年 4 月 15 日~2026 年 4 月 14 日 预计回购金额 1亿元~2亿元 回购价格上限 20.46元/股 □减少注册资本 √用于员工持股计划或股权激励 回购用途 □用于转换公司可转债 □为维护公司价值及股东权益 实际回购股数 13,723,200股 实际回购股数占总股本比例 1.43% 实际回购金额 199,982,725元 实际回购价格区间 13.31元/股~16.09元/股 一、 回购审批情况和回购方案内容 公司本次回购股份符合相关法律法规的规定及公司回购股份方案的要求。本 次回购方案实际执行情况与已披露的回购方案不存在差异，公司已按披露的方案 完成回购。 本次股份回购不会对公司正常经营活动、财务状况及未来发展等产生重大影 响 ...